Analysis– by Offering (Software and Services), Deployment (On-Premises and Cloud), Organization Size (SMEs and Large Enterprises), and Application (Pharmaceutical, Biotechnology, and Medical Devices)
No. of Pages:144
Report Code:
BMIRE00028407
Category:
Technology, Media and Telecommunications
Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market
The Asia Pacific manufacturing execution system in life sciences market is expected to grow from US$ 834.86 million in 2023 to US$ 2,821.07 million by 2033. It is estimated to grow at a CAGR of 12.9% from 2023 to 2033.
Rising Application in Cell and Gene Therapy Sector Fuels Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market
Cell and gene therapy is one of the growing divisions of the healthcare industry. The growth in the clinical adoption of advanced cell therapy is one of the major factors raising the demand for personalized medicines. In addition, the growing demand for cell therapy and the promise it holds further raise the requirement for MES solutions. It is seen that cell therapy is moving from a manual-oriented lab environment to identifying production scale principles to make the process more robust and error-free with reduced costs. In the cell therapy process, MES can help automate the tracking of the patient’s blood cells through the system and thus offer significant valuable insights for the treatment been manufactured. Furthermore, electronic verification of the process negates human error and can improve a lab's throughput. In addition, the MES solution can also help reduce risk by alerting operators about problems that could have catastrophic consequences. Several market players are also providing MES solutions, particularly for cell and gene manufacturing. For example, POMS Corporation provides POMSnet MES. The MES solution helps regulate industry deliveries such as genealogy, material management, and equipment tracking (instruments, safety hoods, centrifuges, and more). Also, the electronic batch record execution helps manufacturers deliver cell therapies faster by streamlining the production workflow with a cloud-based MES.
There is also an increasing number of collaborations between key solution providers of the pharmaceutical manufacturing industry’s ecosystem for developing advanced solutions for cell and gene therapy product manufacturing. In January 2022, TrakCel, a supplier of cellular orchestration solutions for the cell and gene therapy industry, collaborated with Korber for software integration. The collaboration resulted in a functional integration between TrakCel’s OCELLOS and Korber’s PAS-X. It is expected to allow both companies' cell and gene therapy customers to effectively share data detailing manufacturing events and milestones such as starting checks, fill and finish, and product release; and provide full traceability and audit logs. Thus, the growing application and adoption of MES by the market players in cell and gene therapy manufacturing is expected to create an opportunity for the growth of the manufacturing execution system in life sciences market during the forecast period.
Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market Overview
The MES in life sciences market in Asia Pacific is sub-segmented into China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific. Various growing economies in the region are witnessing automation in life sciences industries. The healthcare sector in Asia Pacific is flourishing with growth in foreign investments from western countries, especially from Europe and North America. The manufacturing execution systems bring substantial improvements over paper-based processes. They help pharma manufacturers to create flawless manufacturing processes; reduce risks, time, costs, and efforts; and increase process efficiency and product quality. To surpass China in pharma and biotech capabilities, India is continuously substantiating the ecosystem for pharmaceutical manufacturer in the country. Furthermore, the pharmaceutical industry in India is continuously looking for advanced methods to ease manufacturing operations.
Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market Revenue and Forecast to 2033 (US$ Million)
Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market Segmentation
Based on offering, the Asia Pacific manufacturing execution system in life sciences market is segmented into software and services. The services segment held a larger share of the Asia Pacific manufacturing execution system in life sciences market in 2023.
Based on deployment, the Asia Pacific manufacturing execution system in life sciences market is segmented into on-premises and cloud. The cloud segment held a larger share of the Asia Pacific manufacturing execution system in life sciences market in 2023.
Based on organization size, the Asia Pacific manufacturing execution system in life sciences market is segmented into SMEs and large enterprises. The large enterprises segment held the largest share of the Asia Pacific manufacturing execution system in life sciences market in 2023.
Based on application, the Asia Pacific manufacturing execution system in life sciences market is segmented into pharmaceutical, biotechnology, and medical devices. The medical devices segment held the largest share of the Asia Pacific manufacturing execution system in life sciences market in 2023.
Based on country, the Asia Pacific manufacturing execution system in life sciences market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China dominated the share of the Asia Pacific manufacturing execution system in life sciences market in 2023.
Atachi Systems; ATS Global B.V.; Emerson Electric Co; LZ Lifescience Limited; Rockwell Automation Inc; Schneider Electric SE; and Siemens AG are the leading companies operating in the Asia Pacific manufacturing execution system in life sciences market.
Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market Strategic Insights
Get more information on this report
Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market Segmentation Analysis
Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market Report Highlights
Asia Pacific Manufacturing Execution System (MES) In Life Sciences Report Scope
Report Attribute
Details
Market size in 2023
US$ 834.86 Million
Market Size by 2033
US$ 2,821.07 Million
CAGR (2023 - 2033)
12.9%
Historical Data
2021-2022
Forecast period
2024-2033
Segments Covered
By Offering
Software
Services
By Deployment
On-Premises
Cloud
By Organization Size
SMEs
Large Enterprises
By Application
Pharmaceutical
Biotechnology
Medical Devices
Regions and Countries Covered
Asia-Pacific
China, India, Japan, Australia, Rest of Asia-Pacific
Market leaders and key company profiles
Atachi Systems
ATS Global B.V.
Emerson Electric Co
LZ Lifescience Limited
Rockwell Automation Inc
Schneider Electric SE
Siemens AG
Get more information on this report
Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market Country and Regional Insights
Get more information on this report
Identical Market Reports with other Region/Countries
The List of Companies - Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market
Atachi Systems
ATS Global B.V.
Emerson Electric Co
LZ Lifescience Limited
Rockwell Automation Inc
Schneider Electric SE
Siemens AG
Frequently Asked Questions
How big is the Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market?
The Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market is valued at US$ 834.86 Million in 2023, it is projected to reach US$ 2,821.07 Million by 2033.
What is the CAGR for Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market by (2023 - 2033)?
As per our report Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market, the market size is valued at US$ 834.86 Million in 2023, projecting it to reach US$ 2,821.07 Million by 2033. This translates to a CAGR of approximately 12.9% during the forecast period.
What segments are covered in this report?
The Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market report typically cover these key segments-
Offering (Software, Services)
Deployment (On-Premises, Cloud)
Organization Size (SMEs, Large Enterprises)
Application (Pharmaceutical, Biotechnology, Medical Devices)
What is the historic period, base year, and forecast period taken for Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market?
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market report:
Historic Period : 2021-2022
Base Year : 2023
Forecast Period : 2024-2033
Who are the major players in Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market?
The Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
Atachi Systems
ATS Global B.V.
Emerson Electric Co
LZ Lifescience Limited
Rockwell Automation Inc
Schneider Electric SE
Siemens AG
Who should buy this report?
The Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market report is valuable for diverse stakeholders, including:
Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.
Essentially, anyone involved in or considering involvement in the Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market value chain can benefit from the information contained in a comprehensive market report.
Get Free Sample For Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market
